Alliancebernstein L.P. bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,500 shares of the company’s stock, valued at approximately $175,000. Alliancebernstein L.P. owned about 0.07% of Corvus Pharmaceuticals as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. TIAA CREF Investment Management LLC increased its stake in Corvus Pharmaceuticals by 43.3% in the first quarter. TIAA CREF Investment Management LLC now owns 7,181 shares of the company’s stock valued at $149,000 after acquiring an additional 2,170 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Corvus Pharmaceuticals by 29.3% during the second quarter. Russell Investments Group Ltd. now owns 9,286 shares of the company’s stock valued at $112,000 after buying an additional 2,105 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Corvus Pharmaceuticals during the first quarter valued at about $331,000. Schwab Charles Investment Management Inc. bought a new position in shares of Corvus Pharmaceuticals during the second quarter valued at about $212,000. Finally, Renaissance Technologies LLC bought a new position in shares of Corvus Pharmaceuticals during the first quarter valued at about $1,201,000. 82.57% of the stock is currently owned by institutional investors and hedge funds.
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) opened at $12.13 on Wednesday. Corvus Pharmaceuticals, Inc. has a 1-year low of $8.27 and a 1-year high of $22.14.
Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, November 2nd. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.19. analysts anticipate that Corvus Pharmaceuticals, Inc. will post -2.82 earnings per share for the current fiscal year.
Several analysts recently issued reports on the company. Zacks Investment Research raised Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Tuesday, November 7th. Wedbush reissued an “outperform” rating and issued a $26.00 target price on shares of Corvus Pharmaceuticals in a research note on Tuesday, August 8th. Finally, Credit Suisse Group raised Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 target price on the stock in a research note on Wednesday, August 23rd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $20.25.
ILLEGAL ACTIVITY NOTICE: “14,500 Shares in Corvus Pharmaceuticals, Inc. (CRVS) Purchased by Alliancebernstein L.P.” was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.themarketsdaily.com/2017/11/15/14500-shares-in-corvus-pharmaceuticals-inc-crvs-purchased-by-alliancebernstein-l-p.html.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS).
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.